Last reviewed · How we verify
Selenase
Selenase is a Small molecule drug developed by University Hospital, Basel, Switzerland. It is currently in Phase 3 development. Also known as: Selenase: Selenium.
Selenase is a treatment that involves selenium supplementation, specifically using sodium-selenite, to address various conditions including ischemic stroke, severe sepsis, septic shock, ventricular dysfunction, and cardiac arrest. Clinical trials have been conducted to evaluate the effectiveness of Selenase in these conditions, with one completed trial (NCT02505295) focusing on its impact on ischemic stroke outcome.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Selenase |
|---|---|
| Also known as | Selenase: Selenium |
| Sponsor | University Hospital, Basel, Switzerland |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Selenium for Musculoskeletal Health (PHASE3)
- Trial of Glutamine and Antioxidant Supplementation in Critically Ill Patients (NA)
- Selenium and Ischemic Stroke Outcome (NA)
- High-dose Selenium Supplementation in Patients With Left Ventricular Assist (PHASE3)
- Selenium to Improve Neurological Outcome After Cardiac Arrest (PHASE2)
- Placebo Controlled Trial of Sodium Selenite and Procalcitonin Guided Antimicrobial Therapy in Severe Sepsis (PHASE3)
- Selenium Replacement and Serum Selenium Level in Severe Sepsis and Septic Shock Patients (PHASE2)
- Selenium in the Treatment of Complicated Lymphatic Malformations (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Selenase CI brief — competitive landscape report
- Selenase updates RSS · CI watch RSS
- University Hospital, Basel, Switzerland portfolio CI
Frequently asked questions about Selenase
What is Selenase?
Who makes Selenase?
Is Selenase also known as anything else?
What development phase is Selenase in?
Related
- Manufacturer: University Hospital, Basel, Switzerland — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Selenase: Selenium
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing